Cantor Fitzgerald reissued their buy rating on shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) in a report released on Monday.

“We hosted our annual Cantor Fitzgerald Healthcare Conference in New York today, with HRTX in attendance.”,” the firm’s analyst wrote.

Several other brokerages also recently commented on HRTX. BidaskClub upgraded shares of Heron Therapeutics from a sell rating to a hold rating in a report on Saturday, August 26th. Cowen and Company set a $40.00 target price on shares of Heron Therapeutics and gave the stock a buy rating in a report on Thursday, August 3rd. Aegis reiterated a buy rating and issued a $33.00 target price on shares of Heron Therapeutics in a report on Tuesday, July 18th. Noble Financial reiterated a buy rating on shares of Heron Therapeutics in a report on Thursday, August 10th. Finally, Jefferies Group LLC reiterated a buy rating and issued a $26.00 target price on shares of Heron Therapeutics in a report on Friday, July 14th. One research analyst has rated the stock with a sell rating, one has given a hold rating and twelve have given a buy rating to the company’s stock. Heron Therapeutics currently has a consensus rating of Buy and a consensus price target of $30.20.

Heron Therapeutics (HRTX) opened at 16.00 on Monday. Heron Therapeutics has a 52-week low of $12.21 and a 52-week high of $20.85. The stock’s market capitalization is $866.21 million. The firm has a 50-day moving average of $15.81 and a 200-day moving average of $14.97.

Heron Therapeutics (NASDAQ:HRTX) last announced its earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($0.90) by $0.10. The firm had revenue of $8.51 million during the quarter, compared to the consensus estimate of $4.53 million. On average, equities analysts expect that Heron Therapeutics will post ($3.51) EPS for the current year.

COPYRIGHT VIOLATION NOTICE: “Heron Therapeutics, Inc. (HRTX) Earns Buy Rating from Cantor Fitzgerald” was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another website, it was copied illegally and reposted in violation of U.S. and international copyright & trademark legislation. The legal version of this report can be accessed at https://www.thecerbatgem.com/2017/09/28/heron-therapeutics-inc-hrtx-earns-buy-rating-from-cantor-fitzgerald.html.

Several large investors have recently bought and sold shares of the company. Parametric Portfolio Associates LLC increased its holdings in shares of Heron Therapeutics by 2.3% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 33,910 shares of the biotechnology company’s stock worth $470,000 after purchasing an additional 771 shares during the period. Schwab Charles Investment Management Inc. increased its holdings in shares of Heron Therapeutics by 0.6% during the 2nd quarter. Schwab Charles Investment Management Inc. now owns 170,555 shares of the biotechnology company’s stock worth $2,363,000 after purchasing an additional 1,026 shares during the period. Legal & General Group Plc increased its holdings in shares of Heron Therapeutics by 13.9% during the 1st quarter. Legal & General Group Plc now owns 8,971 shares of the biotechnology company’s stock worth $136,000 after purchasing an additional 1,098 shares during the period. HighTower Advisors LLC boosted its position in shares of Heron Therapeutics by 11.4% during the 2nd quarter. HighTower Advisors LLC now owns 16,584 shares of the biotechnology company’s stock valued at $231,000 after acquiring an additional 1,700 shares in the last quarter. Finally, Tudor Investment Corp ET AL boosted its position in shares of Heron Therapeutics by 10.2% during the 2nd quarter. Tudor Investment Corp ET AL now owns 18,618 shares of the biotechnology company’s stock valued at $258,000 after acquiring an additional 1,724 shares in the last quarter.

Heron Therapeutics Company Profile

Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.

Analyst Recommendations for Heron Therapeutics (NASDAQ:HRTX)

Receive News & Stock Ratings for Heron Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heron Therapeutics Inc. and related stocks with our FREE daily email newsletter.